{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/contentassets/0a8afbeb4c904d14b7b8a773bc25766e/legemiddelforbruket-2012-2016.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "2012-2016 LEGEMIDDELSTATISTIKK ISSN 1890-9647 Norwegian c Health Omr\u00e5det for nettsider: www.fhi.no/ The report is available a s pdf format only and can be downloaded from the www.fhi.no Layout omslag: www.fetetyper.no Kontaktinformasjon/Contact i 1978: Legemiddelforbruket i Norge 1975 - 1977 1980: Legemiddelforbruket i Norge 1975 - 1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruket i Norge 1977 - 1981 1984: Legemiddelforbruket i Norge 1979 - 1983 1985: Legemiddelforbr uket i Norge 1984 1986: Legemiddelforbruket i Norge - 1985 1987: Legemiddelforbruket i Norge 1986 1988: Legemiddelforbruket i Norge 1987 1989: Legemiddelforbruket i Norge 1984 - 1988 1990: Legemiddelforbruket i Norge 1989 1991: Legemiddelforbruket i N orge - 1990 1992: Legemiddelforbruket i Norge 1991 1993: Legemiddelforbruket i Norge 1988 - 1992 1994: Legemiddelforbruket i Norge 1989 - 1993 1995: Legemiddelforbruket i Norge 1990 - 1994 1996: Legemiddelforbruket i Norge 1991 - 1995 1997: Legemiddel forbruket i Norge 1992 - 1996 1998: Legemiddelforbruket i Norge 1993 - 1997 1999: Legemiddelforbruket i Norge 1994 - 1998 2000: Legemiddelforbruket i Norge 1995 - 1999 2001: Legemiddelforbruket i Norge 1996 - 2000 2002: Legemiddelforbruket i Norge 1997 - 2001 2003: Legemiddelforbruket i Norge 1998 - 2002 2004: Legemiddelforbruket i Norge 1999 - 2003 2005: Legemiddelforbruket i Norge 2000 - 2004 2006: Legemiddelforbruket i Norge 2001 - 2005 2007: Legemiddelforbruket i Norge 2002 - 2006 2008: Legemiddelforbru ket i Norge 2003 - 2007 2009: Legemiddelforbruket i Norge 2004 - 2008 2010: Legemiddelforbruket i Norge 2005 - 2009 2011: Legemiddelforbruket i Norge 2006 - 2010 2012: Legemiddelforbruket i Norge 2007 - 2011 2013: Legemiddelforbruket i Norge 2008 - 2012 2014: Legemiddelforbruket i Norge 2009 - 2013 2015: Legemiddelforbruket i Norge 2010 - 2014 2016: Legemiddelforbruket i Norge 2011 - 2015 4 Legemiddelstatistikk 2017 :1FolkehelseinstituttetForord Rapport en Legemiddelforbruket i Norge er den en av rapporten, og den er i det bygget for 2016 p\u00e5 data fra selger nettsiden www.reseptregisteret.no. liste o ver ndringer for etatt 1. januar Rapport en kun i elektronisk format. En pdf fil av . Oslo, mars 2017Preface The report Drug Consumpti on in Norway has been publis hed annually since 1977. The statistics are based on total drug sales from wholsalers. This is th e 39th edition of the report . It is m ainly organiz ed accordi ng to the previous editions and the report is publis hed as a combi ned Norwegian/English edition. The main statistica l chapters for each ATC group are only partly translat ed into English. ATC codes are included for all the substances in order to increas e the understanding . The fir st part of the report i ncludes comments to the total drug consumption. The present edition includes data for the period 2012- 2016. The figures are based on sales from all drug wholesalers in Norway and includ e sales of over the counter medicine s which are available in non pharmacy outlets . All wholesalers in Norway report total sales of medicines directly to th e Norwegian Institute of Publi c Health on a monthly basis . A Norwegi an Prescripti on databas e (NorPD) was from January 2004 establis hed at the Norwegi an Institute of Public Health. NorPD includes prescribing information a t the in dividual patient level from a ll Norwegi an pharmacies. NorPD offers more detailed information about the drug use in the population. More informati on regardi ng the NorPD is availabl e in a separat e annually report and on www.norpd.no . A list of ATC a nd D DD alterations valid from 1 January 2017 is included on p. 91. For more informati on on the statistical presentati on of drug consumption, pleas e confer the introduction. In order to fully underst and the statistical material in this report we recomm end readi ng the introduction. This report is availabl e in electronic fo rmat only. A pdf file can be downloaded from the website: http://www.legemiddelforbruk.no/englis h/ or from www.fhi.no. Requests regarding the statistics can be forwarded by email to lmfin@fhi.no. Oslo, 2017 :1FolkehelseinstituttetContents Preface ................................................................................................................................................................... 4 Introduction ............................................................................................................................................................. 7 The Anatomical Therapeutic Chemical (ATC) classification system ...................................................................... 7 Units of measurement (Defined Daily Dose (DDD) and Costs) .............................................................................. 8 Evaluation and application of drug statistics based on sales figures from wholesalers ........................................ 10 Nordic Statistics ............................................................... ..................................................................................... 10 General comments to consumption trends ........................................................................................................... 11 Total sales .................................................................................................................................................... 11 Prescription Only Medicines (POM) ............................................................................................................. 11 Non-prescription medicines (OTC) ............................................................................................................... 11 Sales of OTC medicines outside pharmacies .............................................................................................. 12 Turnover per ATC main group ...................................................................................................................... 13 County statistics ........................................................................................................................................... 13 Population by age 2012 - 2016 ............................................................................................................................. 19 Abbreviations ........................................................................................................................................................ 20 Statistics for each ATC main g roup A Alimentary tract and metabolism ..................................................................................................................... 21 B Blood and blood forming organs ..................................................................................................................... 29 C Cardiovascular system .................................................................................................................................... 33 D Dermatologicals .............................................................................................................................................. 41 G Genito urinary system and sex hormones ....................................................................................................... 45 H Systemic hormonal preparations, excl. sex hormones and insulins ................................................................ 51 J Antiinfectives for systemic use ........................................................................................................................ 55 L Antineoplastic and ................................................................................................ 61 M -skeletal system . 67 N Nervous system .............................................................................................................................................. 71 P Antiparasitic products, insecticides and repellents .......................................................................................... 79 R Respiratory system ......................................................................................................................................... 81 S Sensory organs ............................................................................................................................................... 87 V Various ............................................................................................................................................................ 89 Alterations in ATC codes and DDDs 201 niv\u00e5), tall for de ulike undergruppene (2., 3. og 4. niv\u00e5) og ned til som viser som er publisert i Felleskatalogen. Introduction The figures in the report represent sales from whole - salers to retailers (pharmacies, hospitals, nursing homes and non -pharmacies outlets) .The statistics include total sales of medicinal products with marketing authorisation in Norway. It should be emphasised that sales from wholesalers are not necessarily equal to what is actually consumed. The source of the data should always be considered when interpreting and evaluating drug use and the necessary limitations should be included in the conclusions. The statistical tables are sorted according to the ATC classification system, and the Defined Daily Dose are used as the unit of measurement. The ATC/DDD version valid from January 2017 is used in this edition . The A natomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into 14 main groups (1st level), then further divided into pharmacological/ therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological /thera - peutic subgroups and the 5th level is the chemical substance . The ATC code A complete classification of spironolactone with the ATC code C03DA01 illustrates the structure of the ATC system: C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic subgroup) . C03D Potassium (3rd level, pharmacological tagonists (4th level, pharmacological subgroup) C03DA01 Spironolactone level, chemical substance) All products containing spironolactone (Aldactone \u00d2 and Spirix\u00d2) are assigned the code C03DA01. The ATC classification system makes it possible to compile drug statistics on 5 different levels, that is, figures showing total consumption of all products classified in main group C - Cardiovascular system (1st level), figures for the various subgroups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. The ATC code for all pharmaceuticals on the Norwegian market is included in the monographs of the national drug catalogue Felleskatalogen . 8 Legemiddelstatistikk 2017 :1Folkehelseinstituttet WHO Collaborating Centre for Drug Statistics Methodology I 1982 opprettet WHO et koordineringssenter ved NMD i Oslo, WHO Collaborating Centre for Drug Statistics Methodology med tilknytning til WHOs Europakontor i med medlemmer fra 12 ulike land. Fra land (f eks bruks- omr\u00e5de og preparater etter bruksomr\u00e5de. The WHO Collaborating Centre for Drug Statistics Methodology In 1982 th e WHO Regional Office for Europe established a coordinating centre at NMD in Oslo; the WHO Collaborating Centre for Drug Statistics Methodology . In May 1996 the Centre was attached to the WHO Headquarter in Geneva due to the increasing global use of the ATC/DDD system. The main tasks of the WHO Centre are to classify drug s according to the ATC system, assign Defined Daily Doses and to further develop the ATC/DDD system. This work is performed in close cooperation with a global expert group representing 12 different countries. As from 2002 t he Centre has been located at the Norwegian Institute of Public Health. Units of measurement The Defined Daily Dose (DDD) Prices change with time, prices differ between alternative preparations and between countries. Statistics based on currency is hence difficult to assess . Other quantities, independent of price changes and changing exchange rates, may offer a better basis for professional evaluations. But, when using quantities such as number of tablets, number of packages etc., comparisons between different drugs used alternatively on the same indications, will often not be possible. The use of DDDs as units of measurement offers better possibilities for comparisons between alternative medicinal products , independ ent of price differences. The evaluation of drug consumption over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults . The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit. Drugs used for more than one indication are a challenge. For antipsychotics the doses used in psychoses and not the lower doses used in the treatment of neuroses, are chosen as the basis for assignment of the DDDs. With the excep tion of some specific pediatric products, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. Drugs with different bioavailabilities for different routes of administrations may, how ever, have more than one DDD, each of them linked to a specific dosage form. For products where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for the DDD. Whenever possible, the DDD is indicated as t he quantity of active substance. When this is impossible, as is the case with combination products and some liquid products, the DDD is given as the number of unit doses (no of tablets, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. Legemiddelstatistikk 2017 :1Folkehelseinstituttet er n\u00e6rmere beskrevet i publikasjonen Guidelines for ATC classification and DDD assignment 201 7, Oslo 2016. En liste med alle fastsatte DDD for usammensatte DDDs ) kan bestilles fra Folkehelseinstitutt et, WHO Collaborating Centre for Drug Statistics Methodology . En s\u00f8kbar en faktor p\u00e5 2.1. The sales are given as the number of DDDs/1000 inhabitan ts/day, calculated as follows: Total consumption measured in DDDs x 1000 3651) x number of inhabitants This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose. For some drug groups mainly used during shorter periods, a presentation of the sales data as the number of DDDs/inhabitant/year may be more convenient. An estimated sale of 5 DDDs/inhabitant/year will indicate that each inhabitant may undergo a treatment of 5 days duration. If the standard treatment last s 7 days, one may alternatively estimate the number of 7 -day courses by dividing the total number of sold DDDs by the course duration . The DDDs used in this book are for most plain products (active ingredients) indicated in adjacent brackets for the respe ctive ATC codes . List of DDDs for fixed combination products is available on the website www.whocc.no . The principles of the ATC/DDD system are more thoroughly described in the publication Guidelines for ATC classific ation and DDD assignment 201 7, Oslo 2016. The ATC I ndex with DDDs includes all assigned DDDs for plain products. Both the Guidelines and the ATC/DDD Index can be ordered from the WHO Centre (order form see the website). The Guidelines and ATC/DDD I ndex are also available from the website of the Centre: www.whocc.no . Sales in DDD For some substances the sale is too low to be given in the statistics. This will be indicated as e.g. 0.00 or 0.0. Costs in Norwegian currency Estimates of the expenditure in NOK for the period 2012- 2016 are included in separate tables for each ATC 3rd level. These tables are included in connection with each ATC main group and the costs are expressed in pharmacy retail price (AUP). The calcul ation of the pharmacy retail price is based on the invoiced pharmacy purchase price with the addition of the pharmacy margin including fees and VAT. There is no price regulation of non- prescription medicines in Norway and it is therefore difficult to estimate the OTC sales in terms of pharmacy retail prices. The Norwegian Institute of Public Health has no information of the actual retail prices for OTC medicines. The retail prices (AUP) for OTC medicines are estimated by using the purchase prices multipli ed with a factor of 2.1. 1) 366 dager ved skudd\u00e5r / 366 days in leap year 10 informative tilt av publikasjon om legemiddelbruk i de nordiske land Medicines Consumption in the Nordic Countries 2004- 2008, ble utgitt i 20 10. Publikasjonen fra NOMESKO p\u00e5 samme nettside. It should be emphasized that the estimated cost given in pharmacy retail prices in this report probably underestimates the actual cost. Figures from the Norwegian Prescription Database (NorPD) (www.norpd.no ) will give the actual cost in pharmacy retail prices of prescription medicines. Evaluation and application of drug statistics Drug statistics based in sale from wholesalers are important basis for medical and health economic assements. The statistics can be used to: - survey consumption, and hence therapy, on different levels and during time - measure the effect of legislative changes and informational efforts - define needs for further investigation of drug therapy traditions The following limitations should however be kept in mind when using the statistics: - all medicaments sold from the wholesalers are not necessarily consumed - sales intended for use in general practice and institutions are not treated separately in this report's statistical material . Nordic Statistics A special publication concerning medicines consumption, Medicines Consumption in the Nordic Countries 2004- 2008, was published in 20 10. The publications can be ordered from the Nordic Medico - Statistical Commi ttee ( website: www.nowbase.org . Figures for 2015 are published in the Health statistics in the Nordic countries 2016 , also available from the website. O msetningen av humane \u00f8kte med hovedgrupper er har 20 10-2013 (tabell 3, figur mens det fra 2014 har en st\u00f8rre kostnadsvekst st\u00f8rste gruppen og utgjorde 25 % av omsetningen i kroner i 2016 (tabell 1, s. 14). I denne gruppen var kostnadsveksten p\u00e5 definerte d\u00f8gndoser i av m\u00e5lt i DDD har v\u00e6rt - ningen i doser (DDD) og 92 % av k roneomsetningen 6. Denne andelen har holdt seg relativt konstant over lang tid. General comments to consumption trends Total sales In 201 6 the total sales of medicinal products with marketing authorisation in Norway totalled 17.4 billion NOK ( pharmacy purchase price, incl. 957 million for veterinary medicines). The estimated retail cos ts (AUP) was around 26 billion NOK in 201 6. The sale of medicines for human use increased by 8.8 % in 2016 and this increase was similar to the increase in 2015 (Figure 1) . The sales according to ATC main g roups are given in table 1 page 15. Sales in NOK (AIP) according to the various prescription groups are shown in Table 2. Non- prescription (OTC) medi cines have represented a stable share of total cost (AIP) of around 8% over time . The calculation of sales in pharmacy retail price is based on the invoiced pharmacy purchase price added the pharmacy margin, fees and VAT (i.e. using the Norwegian Medicines Agency price formula in calculation of the approved maximum retail price). The estimated costs presented in this book may therefore deviate from real costs especially in groups where special purchase agreements exist e.g. for hospitals or pharmacies wher e the purchase prices are lower than the ap proved maximum purchase prices. In these cases, the real pharmacy retail costs may be higher than the estimated pharmacy retail costs (AUP) presented in this book. For prescription medicines, the real costs can b e retrieved from the NorPD (www.norpd.no ). In order to reduce reimbursement costs, changes in price regulations have been introduced in Norway. The \"index price\" system was int roduced in 2003 and this was replaced by t he graded price model in 2005. The graded price model is a stepwise price reduction when generic alternatives are marketed. In addition \"preferred drugs\" have been introduced in some drug groups in different periods in order to reduce costs. All these regu lations have limited the cost increase in the period 2010- 2013 (see table 3 and figure 1), while the increase has been higher from 2014 . The cost increase in the latest years is due to the approval of new very expensive medicines (e.g. HCV, cancer, multipl e sclerosis and some orphan medicines). ATC group L - Antineoplastic and immunomodulating agents continues to be the largest group in terms of costs and accounted for 25 per cent of the total cost in 2016 (table 1 , p. 14). The cost increase in this group was 11% in 2016. The sales volume measured in number of DDDs increased by 3% in 201 6. Sale in DDDs has been relatively constant the latest 10 year period (see figure 1). Prescription Only Medicines (POM) The 201 6 POM turnover amounted to 87% of total number of DDDs and 92 % of sales in terms of cost (AIP) . These fractions have remained relatively constant over i Reseptfrie % av DDD solgt i dagligvarehandelen var 2016 mens ande len solgt dagligvare reseptfrie pakninger) \u00f8kte med % Figur utviklingen i salg av i denne av ibuprofen i over tid. av nesesprayer (oksymetazolin og xylometazolin) \u00f8kte med 8 % i 2016 i forhold til i 2015 . For de ble % i forhold til 2015 (tabell 4b) Non- prescription medicines (OTC) The sales measured in DDDs for OTC medicines were unchanged in 2016 compared to 2015 . OTC medicines acco unted for 13% of total sales measured in DD Ds and about 8 % of total costs (AIP) . These proportions have remained unchanged over time. In 201 6 the total sales of OTC medicines for human use increased by around 8% and amounted to around 1.3 billion NOK ( AIP). See table 2. Since there is no price regulation for OTC medicines, it is difficult to measure the actual cost in pharmacy retail prices (AUP) based on sales from wholesalers. For estimation of AUP for OTC medicines see page 9. Sales of OTC medicines outside pharmacies Retail sale for some nicotine replacement medicines was allowed outside pharmacies from January 2003. From November 2003 this regulation was extended to include a selection of other OTC medicines according to a list issued by the Norwegi an Medicines Agency. The list of medicines allowed for sale in non -pharmacy outlets has been extended over time . However, t he non-pharmacy outlets still sell only a limited number of top selling OTC drugs. Table 4, p. 17, shows the sales of OTC medicines and the proportion of sales in non- pharmacy outlets in 2012- 2016 . An overview of the top selling medicines available also in non- pharmacy outlets is given in the table. The sale in number of DDDs of the top selling drugs in non-pharmacy outlets increas ed by 6% in 2016. The share of sale in non-pharmacy outlets was almost unchanged from 2015 to 2016 (table 4b). Trends 2012- 2016 Analgesics Sales of OTC paracetamol measured in DDD, increased by 1.7% in 2016 while the share sold in non-pharmacy outlets wa s at 55% (Table 4). The overall OTC sales of paracetamol correspond to an amount of 36 tablets per inhabitant. Total sales of paracetamol (pres cription and OTC) increased by 6% in 2016 . Figure 2 shows the trend in total sales of par acetamol in the period 2003- 2016. OTC packages accounted for a share of 39% of total sales of paracetamol in 2016 and this proportion has declined over time. Total number of DDDs for OTC formulations of ibuprofen increased by 1% in 2016 while the total sales of ibuprofen remain ed unchanged. In 201 6 the fraction of OTC sales of ibuprofen in terms of DDDs was 55 % the total sale . Nasal decongestants The sales in DDDs of oxymetazoline and xylometazoline increased by 8% in 2016. The share in non-pharmacy outlets have gradually increased and in and in 2016 the share was 68% for xylometazoline. The proportion of sale in non -pharmacy outlets of the combination product of xylometazoline and ipratropiumbromid (R01AB06) decreased slightly in 2016 compared to (table m\u00e5lt i i 2016, mens andel solgt i dagligvarehandelen gikk noe ned i 2016 2015 (tabell 4). N\u00f8dprevensjon Totalt ble 28 800 doser n\u00f8dprevensjon i 2016 hvorav (7 dagligvare. Totalt antall doser av n\u00f8dprevensjon i dagligvarehandelen i 2016. pr (s. 15) gir en oversikt salg i 2016 per legemiddelgruppe i millione r doser (DDD) og i millioner kroner (AIP). ATC gruppe L - Antineoplastiske og immun modu - lerende midler utgjorde 2 5 % av totalomsetningen av humane legemidler i 2016 og er den gruppen som har st\u00f8rst omsetning i kroner. \u00d8kningen i kroner var p\u00e5 11 %. ATC gruppe L omfatter flere bruk av nye legemidler behandling diabetes type nye av sjeldne metabolske sykdommer har bidratt til veksten i gruppe A, mens i ATC gruppe B er det i hovedsak \u00f8kt bruk av de nye antitrombotiske midlene (DOAK) som har bidratt til veksten. ATC gruppe - Hjerte og kretsl\u00f8p den legemiddelgruppen 2016 den prosentvise \u00f8kningen i ATC gruppe C i antall DDD p\u00e5 2,1 % mens kostnadsveksten var i har \u00f8kt (se figur side 39). Nicotine replacement products The sale measures in DDDs of nicotine replacement products increased by 6% in 201 6. The non - pharmacy share has gradually increased and the share was 47% in 2016 . Antihistamines Sales in DDDs of OTC packages of cetirizine increased by 11% in 2016. The share sold in non- pharmacy outlets decreased slightly in 2016 compared to 2015 (table 4) . Emergency contraceptives 128 800 doses in total were sold in 201 6 of emergency contrace ptives, sale in non-pharmacy outlets was 9 100 doses ( 7%). Total s ale of emergency contraceptives decreased by 9% in 2016. Ella One\u00ae (ulipristal) is now the only available product outside pharmacies. Norlevo\u00ae (leonorgestrel) is still available in pharmacies. Overall EllaOne\u00ae accounted for 80% of total number of D DDs of emergency contraceptives in 2016. Other medicines The number of medicines available in non -pharmacy outlets has been rather stable even though the list of what is permitted to be sold has been changed. The medicines included in table 4 accounted 97% of total sales in non -pharmacy outlets in 2016. Turnover per ATC main group The 201 6 sales per ATC main group measured in million DDDs and in million NOK, pharmacy purchase price (AIP) are given in table 1 (p. 15). ATC group L - Antineoplastic and immunomodulating agents accounted for 25% of total cost in 2016 and is the largest group in terms of cost. Introduction of high cost medicines for use in cancer treatment and increased sales of biological medicines (ATC group L04) for the treatment of e.g. rheumatoid arthritis has contributed to the increased cost . The largest increase in cost in 2016 was in ATC group A- Alimentary tract and metabolism and in B Blood and blood forming organs (table 1) . Increased use of new diabetes type 2 medicines as well as use of expensive orphan medicines has contributed to the increased cost in ATC group A. In ATC group B, the increased cost is mainly due to the increased use of the new antithrombotic agents (DOAC). ATC group C - Cardiovascular system is the larges t group in term of sales in DDDs (table 1). Reducing the risk of cardiovascular diseases is important. Treatment of hypertension and hypercholesterolemia reduces the risk of ischemic heart diseases. In 2016 , the increase in number of DDDs in ATC gr oup C was 2.1% , while cost increase was 10 %. There has been a modest cost increase for cardiovascular medicines due to the introduction of pricing/reimbursement regulations. The sales of cholesterol reducing agents in DDDs increased by 4% in 2016. The used of s tatins increased as well as the use of fixed combinations of statins and ezetimibe (see figure page 39). av antibakterielle midler til i forhold til 2015. Dette skyldes at salget av anti mid systemisk bruk i ATC gruppe redusert fra i 2015 til 18,1 DDD/1000innbyggere/d\u00f8gn redusere antibiotikabruken med 30 % fra 2012 2020. Det har v\u00e6rt en jevn nedgang i perioden 20 13-2016 midler salget (se side 56). Andelen i 2016 var 24 % og denne - Veterin\u00e6re legemidler gikk ned med 12 % i New therapies for treatment of pulmonary arterial hypertension has contributed to the increased cost in ATC group C. Reduction in sales of antiba cterial agents for systemic use (J01)1 In ATC group J Antiinfectives for systemic use , there was a 2% reduction in sales given in doses (DDD) in 2016 compared to 2015. This reduction is due to a decline in sales of antibacterials for systemic use (J01) and this is a positive development. The sales in ATC group J01 decreased from 18.8 in 2015 to 18.1 DDD /1000 inhabitants/day in 2016 (Figure 3), which is reduction of 3.5%. When excluding the sale of methenamine (urinary antiseptic - J01XX05) the reduction is around 5%. The national Action plan against antibiotic resistance in health care aims to reduce the use of antibiotics by 30% from 2012 to the end of 2020. There has been a steady decline in the period 2013 to 2016 ( figure 3). Measured in DDD the reductio n in sale of antibiotics (incl. methenamine) was 13.5% from 2012 to 2016. Sales of the various subgroups of antibiotics in J01 (see figure 3) have been reduced during this period. Phenoxymethyl - penicillin (J01CE02) is the antibiotic accounting for the highest share of the total sales of antibacterials ( see page 5 6). The share in 2016 was 24% and has remained relatively constant over the latest 5 years. Phenoxymethylpenicillin is a narrow spectrum agent and the preferred choice with respect to antibiotic resistance. If the decline in sales of antibacterials continues also in the next years, the goal of the action plan would be reached . Veterinary medicines Sales in ATC group Q - Veterinary medicines decreased by 12% in 201 6. This group includes vaccines and m ost agents used in fish farming. The decrease is mainly due to decreased sales of medicines used in fish farming. 1 For en detaljert oversikt over salget i J01, se side 55 -57/ page 55- 57 for details. ATC hovedgruppe i 6 og endringer i forhold til 2015 . Salg i kroner i p ris fra grossist (AIP) Table 1. Sales of drugs per ATC main gro up in 2016 and changes from 2015 . Sales in NOK in pharmacy purchase price (AIP) ATC hovedgruppe ATC main group Salg i mill DDD Sales in mill DDD Endring i mill DDD Change in mill DDDs % endring i DDD % change in DDDs Salg mill kr (AIP) av totale kostnader (ekskl ATC Q) % share of total cost human medicines L - Antineoplastic and immunomod.1) 38 2 4,6 4 177 404 10,7 25,4 N - Nervous system 434 7 1,7 2 436 84 3,6 14,8 A - Alimentary tract and metabolism 516 21 4,3 1 656 245 17,4 10,1 J - Antiinfectives for use 38 -1 -1,9 1 648 54 3,4 10,0 B - Blood and blood forming organs 236 7 2,8 1 500 214 16,6 9,1 R - Respiratory system 386 15 4,0 1 351 117 9,5 8,2 C - Cardiovascular system 792 16 2,1 1 014 92 10,0 6,2 G - 1 1,0 526 63 13,6 3,2 H - Systemic hormonal preparations 89 3 3,6 393 17 4,4 2,4 S - Sensory organs2) 0,6 2,3 1,9 213 products, etc.3) 25 -1 -3,9 0,2 Sum human medicines 2 911 86 3,0 16 429 1 435 9,6 100 Q - Veterinary medicines3) 957 -133 -12,2 Total 2 911 86 3,0 17 1 302 8,1 Tabell Sales in million NOK (AIP) of medicinal products according to prescription status, 2012 - 2016 (excl veterinary medicines). \u00c5r Year Narcotics (A) Addictive medicines (B) Prescript ion only medicines (C) Over the counter medicines (F) Total sales 2012 380 222 10 723 1 049 12 373 2013 367 215 11 005 1 095 12 682 2014 376 216 12 068 1 152 13 811 2015 385 222 13 149 1 238 14 994 2016 452 237 14 405 1 334 16 429 1) DDDs are only assigned for some medicinal products . 2) DDDs are only assigned for antiglaucoma preparations. 3) DDDs are not assigned for veterinary medicines (ATC Q) and only for some drugs in A TC group D, P and V. 16 3. Sales in billion NOK (AUP) o f medicinal products 2003 - 2016 (excl veterinary medicines) \u00c5r Year Milliarder kr og DDD 2005 - 2016 Figure 1. Per cent annual change in total sales excl veterinary medicines measured in NOK (AUP ) and DDDs 2005 - 2016 -4-20246810 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016Prosent og apotek, 2012 - 2016 Table 4. Sales of the top selling OTC medicines available both in non -pharmacy outlets and in pharmacies, 2012 - 2016 a) Total OTC sale given in DDD/1000 inhabitants/day ATC og virkestoff Active ingredient Bruksomr\u00e5de Indication Total OTC sales in DDD/1000 inhabitants/day 2012 DDDs sold in non -phar macy outlets A TC og virkestoff Active ingredient % in non- pharmacy outlets 2012 2013 2014 2015 2016 M01AE01 ibuprofen1) 39 % 38 % 38 % 40 % 39 % N02BE01 paracetamol1) 50 % 51 % 52 % 54 % 55 % N07BA01 nikotin 35 % 39 % 44 % 47 % 47 % R01AA07 Xylometazolin 62 % 63 % 65 % 67 % 68 % R01AB06 Xylometazolin/ipratropiumbromid - 20 % 30 % 35 % 32 % R06AE07 cetirizin 19 % 23 % 23 % 26 % 23 % 1) R eseptpliktige pakninger er ikke inkludert. Totalt (ibuprofen) og side 72 (paracetamol). Excluding sales of prescription only packages. Total sales see tables on page 68 (ibuprofen) and page 7 2 (paracetamol) les in DDD/1000 inhabitants/day paracetamol (OTC and POM packages) in pharmacies and non- pharmacy outlets 2003- 2016 Figur 3 Salg av antibaketerie lle midler til systemisk bruk (J 01) 1990- 2016 Figure 3 . Sa les of antibacterials for use 05101520 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016DDD/1000 innbygger/d\u00f8gnMetenamin (J01XX05) pr 1. januar Population by age 201 2 - 2016 by 1 4 985 870 372 438 424 921 191 488 259 718 1 703 611 1 379 093 433 275 375 014 426 509 190 264 261 666 1 728 068 1 396 542 109 056 375 744 428 077 190 040 262 789 1 744 961 1 408 723 477 962 220 760 954 433 578 188 886 262 481 1 759 513 1 424 649 502 111 189 879 226 268 95 171 135 392 909 751 734 053 252 563 82 034 Menn 2 588 874 180 242 215 570 91 113 127 144 859 273 705 433 272 108 137 991 Totalt antall 5 213 98 5 370 121 441 838 186 284 262 536 1 769 024 1 439 486 524 671 bbreviations AIP Pharmacy purchase price ATC Anatomical Therapeutic Chemical Classification AUP Pharmacy retail price (estimated) DDD Defined Daily Dose DOAC Direct Acting Oral Anticoagulants ED Unit dose EphMRA European Pharmaceutical Market Research Association MU Million units N (adm.form) Nasal NorPD Norwegian Prescription Database O (adm.form) Oral OTC the counter\", non prescription drugs P (adm.form) Parenteral PDD Prescribed daily dose POM Prescription only (adm.form) Rectal SL (adm.form) Sublingual TD (adm.form) Transdermal TU Thousand units U Units UD Unit dose V (adm.form) Vaginal ATC gruppe A Legemiddelstatistikk 2017 :1Folkehelseinstituttet 21 Ford\u00f8yelsesorganer og stoffskifte - og tannmidler Stomatological preparations (not included) A02 Midler mot syrerelaterte lidelser Drugs for acid related disorders A03 Midler mot lidelser Drugs antinauseants Bile and liver A11 Vitaminer (utelatt) Vitamins (not included) A12 Mineraltilskudd ford\u00f8yelses - og stoffskiftepreparater Other alimen tary tract and metabolism products ATC gruppe A 22 Legemiddelstatistikk 2017 :1Folkehelseinstituttet Salg pr ATC 3. niv\u00e5 for gruppe A - Ford\u00f8yelsesorganer og stoffskifte Sales per ATC 3rd level for ATC group A - Alimentary tract and metabolism mill NOK (AUP) ATC ATC level name 2012 2013 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 A02 DDD is assigned by the WHO Collaborating Centre for Drug Statistics M ethodology. The DDDs used in the table are national DDDs for Norway. 2) Inkluderer salg av preparater uten markedsf\u00f8ringstillatelse i Norge. 3) DDD for kombinasjonen er lik DDD for famotidin. The DDD for the combination is equivalent to the DDD for fam otidine. ATC gruppe A 24 Legemiddelstatistikk 2017 :1Folkehelseinstituttet midler mot ulcus og 1990 -2016 Sales of drugs ulcer and GORD (A02B) 1990 -2016 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 A03 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 inhabitants/dayProtonpumpe - hemmere 25 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 A05 Galle Omfatter kun salg av 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 A07E DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 name (DDD value) 2012 2013 2014 2015 2016 A16 Andre 2017, gruppe A 28 Legemiddelstatistikk 2017 :1Folkehelseinstituttet DDD/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 A16AX ol. (kun salg i kroner) Blood substitutes and perfusion solutions (sales in NOK only) B06 Andre hematologiske midler Other hematological agents Salg pr ATC 3. niv\u00e5 for gruppe B - Blod og bloddannende organer Sales per ATC 3rd level for ATC group B - Blood and blood forming organs mill NOK (AUP)1) ATC ATC level name 2012 2013 2014 B 30 Legemiddelstatistikk 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 DDDs/year ATC ATC level name (DDD value) 2012 2013 2014 2016 inhabitants/day ATC ATC level name :1Folkehelseinstituttet 31 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 DDDs/year ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 B06 Andre hematologiske Conestat alfa (3,5 TU) 22 11 1) B02B K og andre er utelatt. 2) g tabl folsyre ble avregistrert i september 2014, og renin -angiotensin system C10 Lipidmodifiserende midler Lipid modifying agents ATC gruppe C 34 Legemiddelstatistikk 2017 :1Folkehelseinstituttet Salg pr ATC 3. niv\u00e5 for gruppe C - Hjerte og kretsl\u00f8p Sales per ATC 3rd level for ATC group C - Cardiovascular system mill NOK (AUP) ATC ATC level name 2012 2013 2014 inhabitants/day ATC ATC level name (DDD v alue) 2012 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 :1Folkehelseinstituttet 37 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 C09 Midler beta blocking agents (C07) 1990 -2016 DDD/1000 inha bitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 C10 Lipidmodifiserende . 020406080100120140160180200220240260280300 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 inhabitants/dayC09 of statins and ezetimibe 1990 - 2016 given in DDD/1000 inhab./day 020406080100120140 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 protectives D03 Midler til s\u00e5rbehandling Preparations midler Other dermatological preparations De fleste legemidler i ATC gruppe D er til dermatologisk bruk. disse legemidlene. Most of the drugs in ATC group D are for topical use. Only a few oral preparations are given DDDs. Detailed consumption figures are only included for these preparations. ATC gruppe D 42 Legemiddelstatistikk 2017 :1Folkehelseinstituttet Salg pr ATC 3. niv\u00e5 for gruppe D - Dermatologiske midler Sales per ATC 3rd level for ATC group D - Dermatologicals mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 2016 D01A Antifungals DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 effekt p\u00e5 genitalia of the G04 Urologika Urologicals Salg pr ATC 3. niv\u00e5 for gruppe G - Urogenitalsystem og kj\u00f8nnshormoner Sales per ATC 3rd level for ATC group G - Genito urinary system and sex hormones mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 2016 G01A Antiinfectives DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 G01 numbers of vaginal rings ATC ATC level name 2012 2013 2014 2015 2016 G02B name 2012 2013 2014 2015 2016 G03 Kj\u00f8nnshormoner 1) Se ogs\u00e5 ATC gr. P01AB og J01XD. See also ATC er ikke tatt med. 4) The vaginal ring should be replaced every 28 day. This implies that each user needs 13 vaginal rings per year. 5) Ekskl. salg av implantater. Excluding sales of implants. 6) Salg angitt i antall implantater. Sales given in number ATC gruppe 2017 (G03A) 1990 - 2016 Sales of oral and transdermal hormonal contraceptives (G03A) 1990 - 2016 DDD/day ATC ATC level name (DDD value) 2012 2013 2014 (2 mg) Norge. 020000400006000080000100000120000140000160000180000200000220000240000260000280000 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/dayTotal (G03C and G03F) 1990 -2016 DDD/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 G03G 390 330 360 G03GA02 Menopausegonadotropin (75 U) 230 240 260 290 330 G03GA04 Urofolli tropin (75 U) 30 30 60 10 0 G03GA05 Follitropin alfa (75 U) 200 200 190 270 280 G03GA06 Follitropin beta (75 U) 210 200 180 170 180 G03GA08 Koriongonadotropin alfa (0,25 mg) 24 25 26 29 29 39 39 39 37 G03XB02 Ulipristal (5 mg) 3 64 280 490 G03XC01 Raloxifen (60 mg) 720 610 340 310 250 1) ATC code G03GA07, G03GA09 and G03GA30 are not included due to low sales. 020000400006000080000100000120000140000160000180000200000 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 G04BE G04BE30 Papaverin/fentolamin1) 13 13 15 14 15 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 G04C Midler H01 Hypofyse -, til systemisk bruk, ekskl kj\u00f8nnshormoner og insuliner Sales p er ATC 3rd level for ATC group H - Systemic hormonal preparations, excl sex hormones and insulins mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 2016 H01A Anterior DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 H01 av (H03AA01) 1990 - Sales of levothyroxine sodium (H03AA01) 1990 - 2016 DDD/1000 inh abitants/day ATC ATC level name (DDD value) 2012 2013 2014 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 inhabitants/day 54 Legemiddelstatistikk Vaccines (not included) Salg pr ATC 3. niv\u00e5 for gruppe J - Antiinfektiva til systemisk bruk Sales per ATC 3rd level for ATC group J - Antiinfectives for systemic use mill NOK (AUP) ATC ATC level name 2012 2013 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 J01 preparater :1Folkehelseinstituttet 57 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 J01X antibacterials systemic use (J01) 1990 - 2016 1) Se ogs\u00e5 ATC gruppe A07AA, see also ATC group A07AA. 2) Se ogs\u00e5 ATC gruppe G01AF og P01AB, see also ATC group G01AF and til comm ents on page 14. 0510152025 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 inhabitants/dayJ01 inhabitants/ year ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 59 DDD/1000 inhabitants/ year ATC ATC level name (DDD value) 2012 2013 2014 2015 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/ year ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 J05AX niv\u00e5 for gruppe L - Antineoplastiske og immunmodulerende midler Sales per ATC 3rd level for ATC group L - Antineoplastic and immunomodulating agents mill NOK (AUP)1) ATC ATC level name 2012 2013 2014 . ATC gruppe 62 Legemiddelstatistikk 2017 :1Folkehelseinstituttet gram of ac tive ingredient/year ATC ATC level name 2012 2013 71 74 73 94 55 L01AD02 Lomustin 66 98 108 160 156 L01AD04 Streptozocin 535 Kladribin 3 3 3 3 2 L01BB05 Fludarabin 103 108 102 100 97 L01BB06 Klofarabin 2 1 0 1 0 Legemiddelstatistikk 2017 :1Folkehelseinstituttet 63 gram of active ingredient/ye ar ATC ATC level name 2012 2013 2014 L01XC11 Ipilimumab 2 65 115 101 10 L01XC12 Brentuximabvedotin 6 6 6 9 L01XC13 Pertuzumab 4 20 360 837 L01XC14 Trastuzumabemtansin 3 Obinutuzumab angitt i TU (tusen enheter) virkestoff/\u00e5r./ Sales given in (thousand units)/year. ATC gruppe L 64 Legemiddelstatistikk 2017 :1Folkehelseinstituttet gram of active ingredient/year ATC ATC level name 2012 2013 2014 297 410 585 1 3 3 4 L01XX32 Bortezomib 22 26 29 28 32 L01XX35 Anagrelide 83 83 91 102 101 L01XX41 Eribulin 0 2 2 2 2 L01XX42 Panobinostat L01XX43 Vismodegib 29 336 Legemiddelstatistikk 2017 :1Folkehelseinstituttet 65 DDD/1000 inhabitants/ year ATC ATC level name (DDD value) 2012 2013 2014 2015 6 5 6 6 L02AB01 Megestrol (0,16 g) 6 6 5 6 6 L02AE hormonanaloger 615 606 582 560 541 L02AE01 Buserelin (0,11 mg depot implant/1,2 mg N) 9 10 5 3 2 L02AE02 Leuprorelin (0,134 mg depot inj./0,06 223 192 L02AE03 Goserelin mg) 312 313 320 334 347 L02AE04 Triptorelin (0,134 mg) 0 0 299 L02BA01 Tamoxifen (20 mg) 191 279 254 251 268 L02BA03 Fulvestrant (8,3 mg) 21 20 21 772 748 728 473 490 506 545 571 L02BG03 Anastrozol (1 mg) 112 86 69 58 48 L02BG04 Letrozol (2,5 mg) 316 357 389 436 470 L02BG06 Eksemestan (25 mg) 45 47 48 51 53 L02BX Andre hormonantagonister og beslektede substanser 37 51 63 67 65 L02BX02 Degarelix (2,7 mg) 21 26 34 42 45 L02BX03 (1g) 16 25 29 25 20 L03 Immunstimulerende 345 315 248 205 200 L03A Immunstimulerend midler1) 345 315 248 205 200 L03AA02 Filgrastim (0,35 mg) 4 5 5 4 4 L03AA13 Pegfilgrastim (0,3 mg) 35 37 91 66 55 L03AB08 Interferon beta -1b (4 MU) 36 34 25 18 12 L03AB10 Peginte rferon alfa -2b (7,5 L03AB11 Peginterferon alfa -2a (26 mcg) 19 -1a (8,9 mcg) 0 0 L03AX03 BCG vaksine 6 7 7 7 8 L03AX13 Glatiramer acetat (20 mg) 73 68 52 40 36 L03AX16 Plerixafor (16,8 mg) 0 0 0 0 0 salg av preparater uten markedsf\u00f8ringstillatelse 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/ year ATC ATC level name (DDD value) 2012 2013 2014 2015 218 224 L04AA10 Sirolimus (3 mg) 9 10 10 11 11 L04AA13 Leflunomid (20 mg) 78 84 90 97 103 L04AA18 Everolimus (1,5 mg) 42 46 47 48 52 L04AA23 Natalizumab (10 mg) 54 58 57 56 58 L04AA24 Abatacept (27 mg) 8 7 8 257 L04AB05 Certolizumab pegol (14 mg) 28 56 141 177 214 L04AB06 Golimumab (1,66 mg) 66 102 122 125 120 L04AC Interleukinhemmere 40 53 79 102 8 L04AC05 Ustekinumab (0,54 mg) 15 24 44 58 67 L04AC07 Tocilizumab (20 mg) 19 23 28 297 L04AD01 g) 149 140 132 129 125 L04AD02 Tacrolimus (5 mg) 130 139 150 162 172 312 319 L04AX02 Thalidomid (0,1 g) 9 for joint and midler til behandling av bensykdommer Drugs for treatment of bone diseases M09 Andre midler mot muskel - og skjelettsy kdommer Other drugs for disorders of the musculo -skeletal system Salg pr ATC 3. niv\u00e5 for gruppe M - Muskler og skjelett Sales per ATC 3rd level for ATC group M - Musculo -skeletal system mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 2016 M01A Antiinflammatory and 83,9 94,8 7,5 See also ATC group N02B gruppe M 68 Legemiddelstatistikk 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 M01 of antiinflammatory and antirheumatic products, non -steroids (M01A) 1990 - 2016 0102030405060 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 inhabitants/dayTotal DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 M03 ulike indikasjoner. /DDDs :1Folkehelseinstituttet ATC gruppe for gruppe N - Nervesystemet Sales per ATC 3rd level for ATC group N - Nervous system mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 N01A Anesthetics, general N 72 Legemiddelstatistikk 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD acid products intended for use in thrombosis prophylaxis are classified in B01AC, and accordingly not include d in this table. 5) Kombinasjoner med koffein og/eller acetylsalisylsyre. - 2016 Total sales of analgesics, incl. OTC and prescription only packages 1990 - 2016 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 Norge. 051015202530354045 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 2017 :1Folkehelseinstituttet 75 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 Legemiddelstatistikk 2017 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD av psykoleptika and antidepressants (N06A) 1990 - 2016 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 N07 Andre 010203040506070 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016Antidepressiva g ruppe P - Antiparasit\u00e6re midler, insekticider og insektmidler Sales per ATC 3rd level for ATC group P - Antiparasitic products, insecticides, and repellents mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 2016 P01A Agents again st amoebiasis DDD/1000 inhabitants/day ATC ATC level name (DDD 2016 P01 packages ATC ATC 2012 2013 2014 2015 2016 P03 lungesykdom obstructive airway diseases R05 Hoste - og forkj\u00f8lelsesmidler Cough and cold preparations systemisk p\u00e5 respirasjonssystemet Other respiratory system products Salg pr ATC 3. niv\u00e5 for gruppe R - Respirasjonsorganer Sales per ATC 3rd level for ATC group R - Respiratory system mill NOK (AUP) ATC ATC level name 2012 2013 2014 2015 2016 R01A Decongestants and other na sal preparations DDD/1000 inhabitants/day ATC ATC level name (DDD :1Folkehelseinstituttet 83 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 R03AL (dose per kapsel) til 10 mcg er levert dose. 2) Inkluderer (R03) 1990 -2016 Sales of obstructive airway diseases (R03) 1990 -2016 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 R05 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016DDD/1000 inhabitants/dayR03 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 pre parations (sales in NOK only) Salg pr ATC 3. niv\u00e5 for gruppe S - Sanseorganer Sales per ATC 3rd level for ATC group S - Sensory organs mill NOK (AUP) ATC ATC level name 2012 2013 DDD/1000 inhabitants/day ATC ATC level name (DDD volum av endosebeholder. The DDDs are based on administration frequencies and single dose. A single dose corresponds to 0.1 ml or the volum e of one package (for single use packages). 2) Inkluderer salg av preparater uten markedsf\u00f8ringstillatelse agents (not (not included) pr ATC 3. niv\u00e5 for gruppe V - Varia Sales per ATC 3rd level for ATC group V - Various mill NOK (AUP)1) ATC ATC level name 2012 2013 Allergens 38,5 Number of packages/year ATC 2017 :1Folkehelseinstituttet DDD/1000 i nhabitants/day ATC ATC level name (DDD value) 2012 2013 2014 2015 2016 ATC niv\u00e5er der DDD er fastsatt er tatt med. Only ATC levels where DDDs are assigned are included. Legemiddelstatistikk 2017 :1Folkehelseinstituttet 91 Alterations in ATC codes and DDDs valid fr om January 2017 Alterations in ATC codes and DDDs valid from January 2017 are listed below. A cumulative list showing all the ATC/DDD alterations made is also available on the website: www.whocc.no ATC alterations: Previous ATC code ATC level name New ATC code s: ATC ATC level name Previous DDD New DDD G03XB01 mifepristone 0.6 g O 0.2 g O J02AC04 posaconazole 0.8 g O, P 0.3 g O, P 1)Change only valid for prefilled vials/pens used for treatment of non -cancer indications. 2)A new ATC 4th level N02AJ Opioids in combination with non -opioid analgetics has been established. For further details regarding the new clas sification and the ATC alterations, see the website www.whocc.no . In the above list only ATC codes where there are products available in Norway is included. Utgitt av Folkehelseinstituttet Published by Norwegian Institute of Public Health Mars/March 2017 B estilling/Order: Kun til gjengelig som PDF. Lastes ned fra www.fhi.no O nly PDF from "}